首页> 外文期刊>Breast cancer research and treatment. >Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model.
【24h】

Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model.

机译:委内瑞拉马脑炎复制子免疫克服了固有的耐受性,并在大鼠乳腺肿瘤模型中针对“自身”肿瘤相关抗原neu产生了有效的抗肿瘤免疫力。

获取原文
获取原文并翻译 | 示例
       

摘要

Many tumor-associated antigens (TAAs) represent 'self' antigens and as such, are subject to the constraints of immunologic tolerance. There are significant barriers to eliciting anti-tumor immune responses of sufficient magnitude. We have taken advantage of a Venezuelan equine encephalitis-derived alphavirus replicon vector system with documented in vivo tropism for immune system dendritic cells. We have overcome the intrinsic tolerance to the 'self' TAA rat neu and elicited an effective anti-tumor immune response using this alphavirus replicon vector system and a designed target antigen in a rigorous rat mammary tumor model. We have demonstrated the capacity to generate 50% protection in tumor challenge experiments (p = 0.004) and we have confirmed the establishment of immunologic memory by both second tumor challenge and Winn Assay (p = 0.009). Minor antibody responses were identified and supported the establishment of T helper type 1 (Th1) anti-tumor immune responses by isotype. Animals surviving inexcess of 300 days with established effective anti-tumor immunity showed no signs of autoimmune phenomena. Together these experiments support the establishment of T lymphocyte dependent, Th1-biased anti-tumor immune responses to a non-mutated 'self' TAA in an aggressive tumor model. Importantly, this tumor model is subject to the constraints of immunologic tolerance present in animals with normal developmental, temporal, and anatomical expression of a non-mutated TAA. These data support the continued development and potential clinical application of this alphaviral replicon vector system and the use of appropriately designed target antigen sequences for anti-tumor immunotherapy.
机译:许多肿瘤相关抗原(TAA)代表“自身”抗原,因此受到免疫耐受的限制。引发足够数量的抗肿瘤免疫反应存在重大障碍。我们利用了委内瑞拉马脑炎衍生的阿尔法病毒复制子载体系统,该系统具有针对免疫系统树突状细胞的体内趋向性。我们已经克服了对“自身” TAA大鼠neu的固有耐受性,并使用这种alphavirus复制子载体系统和严格的大鼠乳腺肿瘤模型中设计的目标抗原引发了有效的抗肿瘤免疫应答。我们已经证明了在肿瘤激发实验中能够产生50%保护的能力(p = 0.004),并且我们已经通过第二次肿瘤激发和Winn分析证实了免疫记忆的建立(p = 0.009)。确定了次要抗体反应,并支持通过同种型建立T辅助1型(Th1)抗肿瘤免疫反应。在建立有效抗肿瘤免疫力的情况下,存活超过300天的动物未显示自身免疫现象的迹象。这些实验共同支持在侵袭性肿瘤模型中建立针对非突变型“自身” TAA的T淋巴细胞依赖性,Th1偏向的抗肿瘤免疫应答。重要的是,该肿瘤模型受到具有正常发育,时间和解剖学表达的非突变TAA的动物中存在的免疫耐受的限制。这些数据支持该甲病毒复制子载体系统的持续发展和潜在的临床应用,以及适当设计的靶抗原序列在抗肿瘤免疫治疗中的应用。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号